US$ 21.97
flow study glp 1 In FLOW, semaglutide, a GLP-1 RA, reduced the risk of major kidney outcomes, MACE and all-cause mortality in people with T2D and CKD, regardless of baseline mineralocorticoid receptor antagonist use. @ADA_Pubs Read Metabolic rebound after GLP-1 receptor
Description
This figure was 18.3% for FH patients using tirzepatide (the ingredient found in Eli Lillys Mounjaro and Zepbound)

[PMID: 38339186]

No office visits required : The entire process is 100% online, which removes scheduling barriers and works for people in areas without easy access to weight loss specialists

My energy levels have increased

And thats the real question
